Floatz logo

Medroxyprogesterone acetate

Endometrial Neoplasms

Peking University People's HospitalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

42 Active assets in the Endometrial Neoplasms cohort.

Asset / SponsorPhaseRating
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3BB
Epirubicin
Eli Lilly and Company
Phase 3BB
Pembrolizumab
Eli Lilly and Company
Phase 3BB
Cyclophosphamide
Vall d'Hebron Institute of Oncology
Phase 3BB
Carboplatin
Eli Lilly and Company
Phase 3BB

View all 49 →

Same molecule, other indications

Medroxyprogesterone acetate is also rated in:

osteoporosisDormant
BBB
Indicative ·
72 / 100
View asset →
cardiovascular disorderDormant
BB
Indicative ·
65 / 100
View asset →
sickle cell diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →